Your browser doesn't support javascript.
loading
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study.
Semenchuk, Julie; Naito, Yumi; Charman, Susan C; Carr, Siobhán B; Cheng, Stephanie Y; Marshall, Bruce C; Faro, Albert; Elbert, Alexander; Gutierrez, Hector H; Goss, Christopher H; Karadag, Bulent; Burgel, Pierre-Régis; Colombo, Carla; Salvatore, Marco; Padoan, Rita; Daneau, Géraldine; Harutyunyan, Satenik; Kashirskaya, Nataliya; Kirwan, Laura; Middleton, Peter G; Ruseckaite, Rasa; de Monestrol, Isabelle; Naehrlich, Lutz; Mondejar-Lopez, Pedro; Jung, Andreas; van Rens, Jacqui; Bakkeheim, Egil; Orenti, Annalisa; Zomer-van Ommen, Domenique; da Silva-Filho, Luiz Vicente Rf; Fernandes, Flavia Fonseca; Zampoli, Marco; Stephenson, Anne L.
Afiliação
  • Semenchuk J; Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada.
  • Naito Y; UK Trust, London, United Kingdom.
  • Charman SC; UK Trust, London, United Kingdom.
  • Carr SB; Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas's NHS Foundation Trust and Imperial College, London, United Kingdom.
  • Cheng SY; Cystic Fibrosis Canada, Toronto, Canada.
  • Marshall BC; Cystic Fibrosis Foundation, Bethesda, MD, USA.
  • Faro A; Cystic Fibrosis Foundation, Bethesda, MD, USA.
  • Elbert A; Cystic Fibrosis Foundation, Bethesda, MD, USA.
  • Gutierrez HH; Division of Pediatric Pulmonary and Sleep Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Goss CH; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States.
  • Karadag B; Division of Pediatric Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.
  • Burgel PR; National Reference CF center and Respiratory Medicine, Cochin Hospital APHP and Université Paris Cité, Institut Cochin (InsermU1016), Paris, France.
  • Colombo C; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Salvatore M; National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit; Italian CF, Registry, Istituto Superiore di Sanità, Rome, Italy.
  • Padoan R; Italian Cystic Fibrosis Registry, Scientific Board, Rome Italy.
  • Daneau G; Belgian Cystic Fibrosis Registry, Health services research, Department of epidemiology and public health, Sciensano, Belgium.
  • Harutyunyan S; Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia.
  • Kashirskaya N; Research Centre for Medical Genetics, Moscow Regional Research and Clinical Institute ("MONIKI"), Moscow, Russia.
  • Kirwan L; Cystic Fibrosis Registry of Ireland, Woodview House, University College Dublin, Ireland.
  • Middleton PG; Bronchiectasis and CF service, Department of Respiratory & Sleep Medicine, Westmead Hospital, Sydney, Australia.
  • Ruseckaite R; Department of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • de Monestrol I; Department of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm CF Center, Karolinska University Hospital Huddinge, Sweden.
  • Naehrlich L; Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.
  • Mondejar-Lopez P; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Jung A; Department of Pulmonology, University Children`s Hospital Zurich, Zurich, Switzerland.
  • van Rens J; Department of Paediatrics, University Hospital Leuven, Leuven, Belgium, European Cystic Fibrosis Society, Karup, Denmark.
  • Bakkeheim E; National Resource Centre for Cystic Fibrosis, Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
  • Orenti A; Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Laboratory of Medical Statistics, Biometry and Epidemiology "G. A. Maccacaro", Università degli Studi di Milano, Milan, Italy.
  • Zomer-van Ommen D; Dutch CF Foundation (NCFS), Baarn, the Netherlands.
  • da Silva-Filho LVR; Instituto da Criança e do Adolescente HCFMUSP, São Paulo, Brazil.
  • Fernandes FF; Medicine Department, Universidade Federal de Catalão, Catalão, Brazil, Hospital de Base do Distrito Federal, Brasília, Brazil.
  • Zampoli M; Department of Paediatrics and Child Health, University of Cape Town, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.
  • Stephenson AL; Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada. Electronic address: Anne.Stephenson@unityhealth.to.
J Cyst Fibros ; 23(5): 815-822, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39191560
ABSTRACT

BACKGROUND:

Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF).

METHODS:

This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV1) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection.

RESULTS:

A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection.

CONCLUSIONS:

No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estado Nutricional / Fibrose Cística / COVID-19 Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estado Nutricional / Fibrose Cística / COVID-19 Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article